Cargando…

Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung

SARS-CoV-2 infection causes a variety of physiological responses in the lung, and understanding how the expression of SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), and its proteolytic activator, transmembrane serine protease 2 (TMPRSS2), are affected in patients with underlying diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miura, Yoko, Ohkubo, Hirotsugu, Nakano, Akiko, Bourke, Jane E., Kanazawa, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673245/ https://www.ncbi.nlm.nih.gov/pubmed/36405683 http://dx.doi.org/10.3389/fimmu.2022.1028613

Ejemplares similares

Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model
por: Miura, Yoko, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2
por: Wang, Ruoke, et al.
Publicado: (2022)

Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2
por: Sarker, Hassan, et al.
Publicado: (2022)

Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2
por: Lai, Yen-Chung, et al.
Publicado: (2022)

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2022)

Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection
por: Yeung, Stephen T., et al.
Publicado: (2022)

Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
por: Zekri, Latifa, et al.
Publicado: (2023)

Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
por: Di Vito, Clara, et al.
Publicado: (2022)

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2023)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)

Bimodal fibrosis in a novel mouse model of bleomycin-induced usual interstitial pneumonia
por: Miura, Yoko, et al.
Publicado: (2021)

Differential effects of age, sex and dexamethasone therapy on ACE2/TMPRSS2 expression and susceptibility to SARS-CoV-2 infection
por: Shahbaz, Shima, et al.
Publicado: (2022)

Asthma Associated Cytokines Regulate the Expression of SARS-CoV-2 Receptor ACE2 in the Lung Tissue of Asthmatic Patients
por: Saheb Sharif-Askari, Fatemeh, et al.
Publicado: (2022)

Identification of the SARS-CoV-2 Entry Receptor ACE2 as a Direct Target for Transcriptional Repression by Miz1
por: Yang, Jing, et al.
Publicado: (2021)

Possible contribution of rare alleles of human ACE2 in the emergence of SARS-CoV-2 variants escaping the immune response
por: Devaux, Christian A., et al.
Publicado: (2023)

SARS-CoV-2/ACE2 Interaction Suppresses IRAK-M Expression and Promotes Pro-Inflammatory Cytokine Production in Macrophages
por: Pantazi, Ioanna, et al.
Publicado: (2021)

Hypercapnia increases ACE2 expression and pseudo-SARS-CoV-2 entry in bronchial epithelial cells by augmenting cellular cholesterol
por: Chen, Fei, et al.
Publicado: (2023)

Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19)
por: Bourgonje, Arno R, et al.
Publicado: (2020)

SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage
por: Sui, Yongjun, et al.
Publicado: (2021)

Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis
por: Albini, Adriana, et al.
Publicado: (2021)

Simian Immunodeficiency Virus Infection Mediated Changes in Jejunum and Peripheral SARS-CoV-2 Receptor ACE2 and Associated Proteins or Genes in Rhesus Macaques
por: Boby, Nongthombam, et al.
Publicado: (2022)

Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22)
por: Wu, Xilin, et al.
Publicado: (2022)

Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages
por: Aw, Zhen Qin, et al.
Publicado: (2022)

DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice
por: Persson, Gry, et al.
Publicado: (2023)

Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies
por: Shah, Masaud, et al.
Publicado: (2022)

Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2
por: Barbier, Mariette, et al.
Publicado: (2022)

Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor
por: Andrade, Sonia Aparecida, et al.
Publicado: (2022)

Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy
por: Inal, Jameel M.
Publicado: (2020)

Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology
por: Dubey, Abhishek, et al.
Publicado: (2020)

ACE and ACE2 Gene Variants Are Associated With Severe Outcomes of COVID-19 in Men
por: Martínez-Gómez, Laura E., et al.
Publicado: (2022)

Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection
por: Sim, Kyu-Young, et al.
Publicado: (2022)

The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model
por: Dickson, Alexandria, et al.
Publicado: (2023)

The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
por: Khatri, Indu, et al.
Publicado: (2020)

Schizophyllum commune Reduces Expression of the SARS-CoV-2 Receptors ACE2 and TMPRSS2
por: Sun, Te-Kai, et al.
Publicado: (2022)

Impact of SARS-CoV-2 mRNA vaccine on arthritis condition in rheumatoid arthritis
por: Takatani, Ayuko, et al.
Publicado: (2023)

Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness
por: Faisal, H.M. Nasrullah, et al.
Publicado: (2021)

Corrigendum: Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
por: Khatri, Indu, et al.
Publicado: (2021)

Sinonasal pathophysiology of SARS‐CoV‐2 and COVID‐19: A systematic review of the current evidence
por: Gengler, Isabelle, et al.
Publicado: (2020)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lhgund2in18ehnrfju6c6aov9